Patient Derived Xenografts Expand Human Primary Pancreatic Tumor Tissue Availability for ex vivo Irreversible Electroporation Testing

Frontiers in Oncology
Rebecca M BrockIrving C Allen

Abstract

New methods of tumor ablation have shown exciting efficacy in pre-clinical models but often demonstrate limited success in the clinic. Due to a lack of quality or quantity in primary malignant tissue specimens, therapeutic development and optimization studies are typically conducted on healthy tissue or cell-line derived rodent tumors that don't allow for high resolution modeling of mechanical, chemical, and biological properties. These surrogates do not accurately recapitulate many critical components of the tumor microenvironment that can impact in situ treatment success. Here, we propose utilizing patient-derived xenograft (PDX) models to propagate clinically relevant tumor specimens for the optimization and development of novel tumor ablation modalities. Specimens from three individual pancreatic ductal adenocarcinoma (PDAC) patients were utilized to generate PDX models. This process generated 15-18 tumors that were allowed to expand to 1.5 cm in diameter over the course of 50-70 days. The PDX tumors were morphologically and pathologically identical to primary tumor tissue. Likewise, the PDX tumors were also found to be physiologically superior to other in vitro and ex vivo models based on immortalized cell lines. We utiliz...Continue Reading

References

Nov 1, 1956·Circulation Research·C F KAY, H P SCHWAN
Feb 13, 2007·Nature Genetics·Roman K ThomasLevi A Garraway
Dec 4, 2012·Biophysical Journal·Christopher B ArenaRafael V Davalos
Jun 7, 2013·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Jason ChiangChristopher L Brace
Sep 11, 2014·The New England Journal of Medicine·David P RyanNabeel Bardeesy
Sep 19, 2015·Seminars in Radiation Oncology·Christopher D WilleyGeorge Yancey Gillespie
Aug 11, 2017·Cell & Bioscience·Wei ShenZhi-Qiang Tian
Sep 26, 2017·International Journal of Cancer. Journal International Du Cancer·Siqi GuoStephen J Beebe
Nov 18, 2018·Conference Proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society·Natalie Beitel-WhiteRafael V Davalos
Jan 25, 2019·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Qi ShaoJohn C Bischof
Sep 24, 2019·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Timothy J O'BrienRafael V Davalos

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
biopsy
pancreatectomy
xenografts
biopsies

Software Mentioned

COMSOL
COMSOL Multiphysics
Ingenuity Pathway Analysis ( IPA )
IPA
AngioDynamics
Heatmapper

Related Concepts

Related Feeds

Cell Fate Conversion By mRNA

mRNA-based technology is being studied as a potential technology that could be used to reprogram cell fate. This technique provides the potential to generate safe reprogrammed cells that can be used for clinical applications. Here is the latest research on cell fate conversion by mRNA.